Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.
about
Emerging Threats in Antifungal-Resistant Fungal PathogensMechanisms of Candida biofilm drug resistanceAdvances in the treatment of invasive neonatal candidiasisEpidemiology and risk factors for invasive candidiasisCan host receptors for fungi be targeted for treatment of fungal infections?Evolution and Application of Inteins in Candida species: A ReviewAre the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their AccuracyT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasisDeclining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillancePreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel EchinocandinRegional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells.Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in ShanghaiRole of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year periodEpidemiology of candidemia in Latin America: a laboratory-based survey.Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United StatesEmerging Infections Program as Surveillance for Antimicrobial Drug ResistanceNovel nanoscale bacteriophage-based single-domain antibodies for the therapy of systemic infection caused by Candida albicans.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Echinocandin Resistance in Candida.An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal PathogensEtest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia.Temporal Trends of the Clinical, Resource Use and Outcome Attributes of ICU-Managed Candidemia Hospitalizations: A Population-Level Analysis.Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogrOutbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit.Sequence-identification of Candida species isolated from candidemia.Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002-20121Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.The risk and clinical outcome of candidemia depending on underlying malignancy.
P2860
Q26750816-5BD5F040-CEF3-4A56-85D1-617B525A5772Q26827521-5F03436A-267B-4934-8B30-04DE3FA0786BQ27022585-9D3D8856-585D-4A62-8989-B9E59C483845Q27024911-F8188E18-53D4-4E87-97CE-254EA24BCB06Q27026653-B55F5FB8-4741-4295-A4F4-7D1AE3853003Q28078765-A49D55DE-6CA6-41A9-B111-694DA88CAE83Q28084765-EF6B4D07-74AC-4000-98A4-A1E15E6AFA7EQ28084998-5EF56732-C1EC-4454-8479-CDBDA700FC27Q28545137-2B3F033A-FC91-4F30-BF6A-2CEB1EDF85C6Q28821330-37C798A1-1ADB-4F09-B713-59DEBE88D231Q30826889-723513AC-BA4A-49BA-BFA2-5A36D430B535Q30834974-A65F8BF5-49C0-4680-86C8-CA0160258B36Q30938136-26D6431A-F225-44A6-B29C-E307C64C1CBCQ31032549-41FEAE55-AF06-4C55-BCDE-93C23E58621EQ33603993-69BC8809-84DD-401C-AF6F-C7EFA5CBE813Q33661367-E1255B6B-4584-4A4B-BC2A-1B87E18D4611Q34058099-8E10D830-3ED2-4579-B972-A368BF4ED2FFQ34100598-EBE91004-D7D5-42F7-A037-B18E28FE0F95Q34252030-530A6190-6A34-4D84-8027-1C44811CD030Q34635088-C468144E-3869-443A-B263-BBEF18B8A2ACQ35746090-0B7E1C3C-B36D-46EC-840C-2D303E690C4BQ35997443-C9E3B999-2C8E-4EDD-AC14-C5E172981C99Q35997516-9A8F8C9E-8885-4026-9557-A4A14DF1E4E0Q36112280-AD974928-493D-4DD5-B37C-BB3E0ADA77A0Q36158489-4DEC8F1D-5864-4161-970C-3FF88383710AQ36276186-A4C815E6-8BD7-4A76-BDAF-96EC357EF9DBQ36304381-89700671-75AE-4907-8720-72E1B828B72AQ36385474-56364507-76D3-42C4-95F5-5F772F849211Q36620896-22A9363F-DF23-4D33-BF14-0B142F8DA486Q36658546-38B37236-D0AD-4081-9764-95423A5D101AQ36667530-4BAA0C5C-9C20-4100-87AF-4406BA6865F9Q36933437-DCB426D2-07EB-4777-B49B-77B59DCE8680Q37036246-58DBD059-5FD5-4E97-8396-1A300A0864B8Q37192581-0C98C00E-01C3-4ED0-8CAD-42441389A155Q37304217-52CE673F-59F6-42A0-BD19-CEDF78DCF5A3Q37524695-7400A672-57FB-4A4D-B251-1A8BF7A0F79DQ37528498-13FE82FE-5A82-4BDA-AB63-0A27308B3C5AQ37612980-0A7C55C2-1823-4344-9500-BFFD62A4172AQ37643499-65D55918-01B5-4106-A804-E8EEAE7575A1Q37742252-7906DD17-3846-4F09-A0BD-46CE1E7E60D7
P2860
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@ast
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@en
type
label
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@ast
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@en
prefLabel
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@ast
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@en
P2093
P2860
P356
P1476
Changes in incidence and antif ...... anta and Baltimore, 2008-2011.
@en
P2093
Angela Ahlquist Cleveland
Benjamin J Park
Betsy Stein
Gordana Derado
Lee H Harrison
Monica M Farley
Rosemary Hollick
Shelley S Magill
Tom M Chiller
P2860
P304
P356
10.1093/CID/CIS697
P407
P577
2012-08-14T00:00:00Z